In two new studies recently published in the Journal of Clinical Medicine and Pharmacy, the researchers proved that regular administration of [melatonin](https://ul.orna.me/KOge/librarybiomarker?id=1863) at doses of 10 mg/kg body weight per day prevents damage to kidney cells (nephrons) and the development of renal failure. ## Initial melatonin research This research began 10 years ago when these same scientists investigated the effects of melatonin on the body as part of research into circadian rhythms and the development of sleep regulators. An unexpected effect they found was that melatonin reduced the increased production of free oxygen radicals (responsible for oxidative stress). Since then, other studies have shown that abnormally high oxidative stress leads to loss of kidney function, development of [renal failure](https://ul.orna.me/KOge/librarydisease?id=25), and the need for hemodialysis or transplantation. ## Evidence base Based on these findings, scientists have conducted experiments on mice, and the results were more than convincing: the systematic administration of melatonin in experimental mice decreased damage to nephrons, decreased [creatinine](https://ul.orna.me/KOge/librarybiomarker?id=139) (a better marker of kidney function), and improved kidney structure. According to Ahmad Agil, the lead author of this study, "Kidney damage can be caused by metabolic complications of obesity, such as diabetes, hypertension, blood lipid metabolism disorders or fatty liver disease. Our main goal is to find a safe way to slow or stop this process, and melatonin may be the best possible solution. We look forward to approval for a human clinical trial, as there are no side effects or risks in our proposed methodology." __Sources__: Ahmad Agil et al, Melatonin Improves Mitochondrial Dynamics and Function in the Kidney of Zücker Diabetic Fatty Rats, Journal of Clinical Medicine (2020). DOI: 10.3390/jcm9092916 Samira Aouichat et al, Melatonin Improves Endoplasmic Reticulum Stress-Mediated IRE1α Pathway in Zücker Diabetic Fatty Rat, Pharmaceuticals (2021). DOI: 10.3390/ph14030232